One year after BridgeBio and its partners won accelerated approval for liver cancer drug Truseltiq (infigratinib), the company is pulling a planned Phase III program after its partner announced plans to permanently discontinue distribution of the drug on Wednesday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,